The Type 1 Diabetes Prevention Trial

(If you're not yet a fan, join us now by clicking the Like button)

The Type 1 Diabetes Prevention Trial, also known as the Intranasal Insulin Trial (INIT II), is part of a coordinated global effort to develop a vaccine for type 1 diabetes. The trial, which began in 2006, is jointly funded by the National Health and Medical Research Council (NHMRC) and the Juvenile Diabetes Research Foundation (JDRF), through the Diabetes Vaccine Development Centre (DVDC).

If successful, this vaccine could prevent type 1 diabetes and the need for daily insulin injections in people at risk.

Who can participate?

Before someone is diagnosed with diabetes, there is a period of time, often many years, when there are no symptoms, but the body’s immune system has already begun attacking the insulin-producing cells in the pancreas. This time provides a potential opportunity to prevent further destruction of the beta cells and thus the onset of type 1 diabetes.

If you or your child are aged between 4 and 30 and are a relative of someone with type 1 diabetes you may be at higher risk of developing type 1 diabetes than others in the general population. By testing a blood sample, we can determine your risk of developing type 1 diabetes. The blood is tested for three different antibodies that show if your immune system has started attacking the beta cells in the pancreas. If you have two or more antibodies, you have a high risk of developing diabetes and may be eligible to participate in the nasal insulin vaccine trial. It is important to note that only 2% of relatives tested will be considered high risk. The remaining 98% can be reassured that their risk is low.

If you have antibodies and are at risk of developing type 1 diabetes you will be offered further free testing to measure your ability to produce insulin. Your out of pocket expenses related to travel will be reimbursed.

If the glucose tests are normal you would be eligible to participate in the trial.

This is a placebo-controlled trial. Therefore, people in the trial receive either the active treatment or a placebo (dummy) treatment. Neither the researchers nor those in the trial know what is in the nasal spray until the end of the trial. This method is used in clinical trials of new medicines to find out if a treatment really works. Every person participating in the trial is vital in finding out if type 1 diabetes can be prevented.

For more information:

Stop Diabetes Australia

Comments are closed.